|
|
Volumn 70, Issue 3, 2012, Pages 471-475
|
|
A phase i trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOPLATIN;
PACLITAXEL;
PANOBINOSTAT;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
ADULT;
ADVANCED CANCER;
AGED;
ALOPECIA;
ANEMIA;
ARTICLE;
BILE DUCT CARCINOMA;
BLADDER CANCER;
BLOOD TOXICITY;
BONE MARROW SUPPRESSION;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CARCINOMA;
CHEMOTHERAPY INDUCED EMESIS;
CLINICAL ARTICLE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DESQUAMATION;
DIARRHEA;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG DOSE ESCALATION;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG ERUPTION;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
ELECTROCARDIOGRAPHY MONITORING;
ESOPHAGUS CANCER;
FATIGUE;
FEBRILE NEUTROPENIA;
FEMALE;
HUMAN;
INFECTION;
LUNG NON SMALL CELL CANCER;
LUNG SMALL CELL CANCER;
MALE;
MAXIMUM TOLERATED DOSE;
MELANOMA;
MESOTHELIOMA;
MULTIPLE CYCLE TREATMENT;
NEUROENDOCRINE TUMOR;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
QT PROLONGATION;
RECOMMENDED DRUG DOSE;
RISK ASSESSMENT;
SENSORY NEUROPATHY;
SOLID TUMOR;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
ADMINISTRATION, ORAL;
ADULT;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
HUMANS;
HYDROXAMIC ACIDS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
NEOPLASMS;
PACLITAXEL;
TREATMENT OUTCOME;
|
|
EID: 84866358085
PISSN: 03445704
EISSN: 14320843
Source Type: Journal
DOI: 10.1007/s00280-012-1931-x Document Type: Article |
|
Times cited : (20)
|
|
References (9)
|
